Immune Signaling and Eczema: Why Chronic Skin Flares Happen
If you live with chronic eczema (atopic dermatitis), you already know it’s more than “just dry skin.” The redness, relentless itching, thickened patches, and recurring flares are driven by changes in the immune system that directly affect the skin barrier, and even the nerves in the skin. Understanding how immune signaling works in eczema helps explain why symptoms persist and why modern treatments increasingly target the immune response itself.
What Happens to the Skin Barrier in Eczema?
Healthy skin acts as a protective barrier, keeping moisture in and irritants, allergens, and microbes out. In many people with atopic dermatitis, structural proteins such as filaggrin are reduced, weakening this barrier. When the barrier is compromised, the skin loses water more easily, leading to dryness and cracking, and becomes more vulnerable to environmental triggers.
But barrier damage doesn’t just cause dryness; it also activates the immune system. Skin cells begin releasing signaling molecules that alert immune cells, setting off inflammation. In eczema, this immune response becomes amplified and chronic rather than protective.
The Immune System’s Role in Chronic Eczema
Most eczema is characterized by an overactive “Type 2” immune response. Immune cells release cytokines (small chemical messengers), including interleukin-4 (IL-4), interleukin-13 (IL-13), and interleukin-31 (IL-31). These cytokines are central to chronic skin inflammation in atopic dermatitis.
IL-4 and IL-13 worsen barrier dysfunction by reducing production of key structural proteins in the skin. This creates a vicious cycle: weaker barrier → more immune activation → more inflammation → further barrier breakdown. Clinically, this contributes to persistent redness, swelling, and dry, irritated skin.
IL-31 plays a particularly important role in chronic itching. Often referred to as an “itch cytokine,” IL-31 can bind directly to receptors on sensory nerves in the skin, triggering the urge to scratch. This explains why eczema itch can feel intense and disproportionate to what’s visible on the surface. Scratching then causes further barrier damage and inflammation, reinforcing the itch–scratch cycle that defines chronic eczema.
Why Eczema Itch Is So Intense
Eczema is not only an immune condition; it also involves the nervous system. Cytokines such as IL-31, IL-4, IL-13, and thymic stromal lymphopoietin (TSLP) can directly activate and sensitize nerve fibers in the skin. Research shows that these immune signals increase nerve density and responsiveness, meaning the skin becomes more reactive over time and more prone to chronic inflammation.
For patients with chronic skin disease, this helps explain why itching can persist even when the rash seems mild, and why stress or minor irritants can trigger major flares. The immune system is effectively “talking” to the nerves, and the nerves respond with itch.
The JAK-STAT Pathway and Persistent Inflammation
One of the most important signaling systems involved in eczema is the JAK-STAT pathway. This pathway translates immune signals into gene expression that sustains inflammation in the skin. When cytokines such as IL-4, IL-13, or IL-31 bind to receptors on immune and skin cells, they activate enzymes called Janus kinases (JAKs). These enzymes then switch on proteins known as STATs, which move into the cell nucleus and turn on genes that promote inflammatory molecules, barrier disruption, and ongoing immune activation.
In chronic eczema, this pathway remains overactive, meaning inflammatory signals are continuously reinforced rather than shut down. The result is persistent redness, itching, and recurring flare cycles.
Other pathways, including NF-κB and MAP kinase signaling, further promote the production of inflammatory molecules. These signaling cascades help explain the visible features of eczema: redness, warmth, swelling, and thickened skin over time.
Because these pathways drive ongoing inflammation, they are now targets of advanced eczema treatments such as biologic therapies and JAK inhibitors, which are designed to interrupt specific immune signals rather than suppressing the entire immune system.
Acute vs. Chronic Eczema: Why Symptoms Change Over Time
In early or acute flares, the Type 2 (Th2) immune response tends to dominate. As eczema becomes chronic, additional immune pathways, including Th1, Th17, and Th22 responses, may become involved. This broader immune activation contributes to long-standing inflammation, skin thickening (lichenification), and persistent disease activity.
This evolving immune pattern helps explain why chronic eczema can feel different over time and why treatment often requires a personalized, layered approach.
Bringing It Together: Immune Signaling Explains the Symptoms
When we connect immune signaling to symptoms, the picture becomes clearer:
Dry, cracked skin → Barrier protein reduction and water loss
Redness and swelling → Cytokine-driven inflammation and immune cell recruitment
Severe itching → Direct activation of sensory nerves by IL-31 and related signals
Chronic flares → Amplified intracellular signaling (JAK-STAT, NF-κB) sustaining inflammation
Eczema is not simply a surface condition — it is a chronic immune-mediated skin disease. Understanding this helps patients move beyond the idea that they just need “better moisturizers” and toward strategies that support barrier repair while addressing immune dysregulation.
For individuals living with chronic skin conditions like atopic dermatitis, targeting immune signaling, alongside strengthening the skin barrier, represents a more complete and sustainable path toward reducing flares and calming inflammation.
